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Summary The relationship between aspirin use and colorectal cancer risk was examined by a case-control study in Italy. Regular aspirin use
was reported by only 47 (3.5%) cases and 77 (4.1%) control subjects, giving a multivariate odds ratio (OR) of 0.7 (95% Cl 0.5-1.0) after
allowance for education, physical exercise and selected dietary factors.
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At least six case-control studies (Kune et al, 1988; Rosenberg et al,
1991; Suh et al, 1993; Muscat et al, 1994; Peleg et al, 1994), based
on over 3700 cases, have suggested that the risk of colorectal
cancer may be reduced in regular aspirin users. Likewise, four
(Thun et al, 1991, 1993; Schreinemachers and Everson, 1994;
Giovannucci et al, 1994, 1995) out of five (Paganini-Hill et al,
1989; Paganini-Hill, 1994) cohort studies showed a protection of
between 20% and 40% among regular aspirin users, although in the
American Nurses' Health Study (Giovannucci et al, 1995) the
protection was only evident for frequent use (2 four times per
week) and after 20 years of use. Thus, the role of time factors,
including latency, in the possible relationship between aspirin and
colorectal cancer are not yet fully understood (Paganini-Hill, 1994;
Greenberg and Baron, 1996). In addition, few studies have investi-
gated the potential confounding role of factors such as diet and
exercise. We have therefore examined aspirin use and certain
lifestyle factors in a case-control study in Italy.
SUBJECTS AND METHODS
The data were derived from a case-control study of colorectal
cancer, conducted between January 1992 and June 1996 in six
Italian areas: Greater Milan; the provinces of Pordenone and
Gorizia; the urban area of Genoa; the province of Forli, in northern
Italy; the province of Latina in central Italy; and the urban area of
Naples, in southern Italy. Only 2.4% of cases and 3.2% of controls
approached for interview refused to participate. Information on
aspirin was included from January 1993.
Cases were 1357 subjects with incident, histologically
confirmed colorectal cancer, admitted to the major teaching and
general hospitals within the area of study. For 860 cases, the site of
origin of the cancer was the colon and for 497 the rectum. Controls
were 1891 subjects residing in the same geographical areas who
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had been admitted to the same hospitals in which cases had been
identified for acute conditions unrelated to known or likely risk
factors for colorectal cancer. Of these, 23% had traumatic condi-
tions, 27% acute non-traumatic orthopaedic disorders, 19% acute
surgical conditions, 22% eye diseases and 9% miscellaneous other
illnesses, such as ear, nose and throat and dental disorders.
The structured questionnaire included information on personal
characteristics, education and other socioeconomic factors, general
lifestyle habits, such as smoking, alcohol and coffee consumption,
a validated food frequency section (based on 79 foods, food groups
or recipes; Franceschi et al, 1993), a few indicators of physical
activity (occupational and leisure time), gynaecological and
obstetric data, related medical history, and history of lifetime use of
aspirin, including indication, time, frequency and duration of use
before diagnosis of the disease which led to hospital admission.
A comprehensive list of major aspirin-containing preparations
(including most common combinations of multiple non-steroidal
antiinflammatory drugs, NSAIDS) in Italy was supplied.
Odds ratios (ORs) of colorectal cancer, and the corresponding
95% confidence intervals (CI), according to various measures of
aspirin use were derived using unconditional multiple logistic
regression (Breslow and Day, 1980), including terms for study
centre, sex, quinquennia of age, education (< 7, 7-11, 2 12 years),
marital status (never married, married), family history of
colorectal cancer (yes/no), measures of energy intake (quintiles),
alc!hol drinking (abstainer, plus tertiles), vegetable and meat
intake (approximate tertiles) and an overall indicator of physical
exercise (approximate tertiles).
RESULTS
Table 1 gives the distribution of colorectal cancer cases and of the
control group according to sex, age, education and family history.
Cases were 793 men and 564 women, aged 23-74 years (median
age 62 years); controls were 1253 men and 638 women, aged
20-74 years (median age 59 years). Cases reported a family
history of colorectal cancer more frequently in first-degree
relatives, while there was no appreciable difference for education.
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Table 1 Distribution of 1357 cases of colorectal cancer and 1891 controls according to sex, age and

































































Various measures of aspirin use are examined in Table 2. A total
of 47 (3.5%) cases vs 77 (4.1%) controls reported regular use (more
than four times per week for > 6 months) of aspirin. The corre-
sponding multivariate odds ratio was 0.7 (95% Cl 0.5-1.0). The risk
tended to decrease with increasing duration of use (OR = 0.6 for use
> 2 years) and was somewhat lower among current users (OR = 0.6).
No material pattern of risk was observed with reference to time since
first, last use or indication (pain vs antithrombosis). The protection
was appreciably, though not significantly, stronger for rectal (OR =
0.4) than for colon cancer (OR = 0.9). The association was also
somewhat stronger in women (OR = 0.5) and below age 60 years
(OR = 0.6), although the interaction terms were not significant.
DISCUSSION
This study provides further support for the hypothesis that aspirin
may decrease the risk of colorectal cancer, which is of interest as it
is based on a southern European population with specific patterns
of aspirin use and prevalence of exposure to dietary and other
possible correlates of colorectal cancer.
Table 2 Relationship between various measures of aspirin use and colorectal cancer risk. Italy, 1993-96
Colorectal cancer cases Controls Odds ratio (95% CI)a
No. % No. %
Non-users 1310 96.5 1814 95.9 1 b
Regular users 47 3.5 77 4.1 0.7 (0.5-1.0)
Duration of use (years)c
< 2 14 1.0 20 1.1 0.9 (0.5-1.7)
22 32 2.4 56 3.0 0.6 (0.4-1.0)
Time since first use (years)c
< 5 19 1.4 29 1.5 0.8 (0.4-1.5)
2 5 28 2.1 46 2.4 0.7 (0.4-1.2)
Time since last usec
< 1 year and current 25 1.8 47 2.5 0.6 (0.4-1.0)
2 1 years 21 1.5 28 1.5 0.9 (0.5-1.6)
lndicationc
Pain 20 1.5 33 1.7 0.7 (0.4-1.2)
Antithrombosis 25 1.8 43 2.3 0.7 (0.4-1.2)
Site
Colon 37 4.3 - - 0.9 (0.6-1.4)
Rectum 10 2.1 - - 0.4 (0.2-0.9)
aObtained from multiple logistic regression equations including terms for age, sex, centre, education, body mass index, total energy, alcohol and meat intake,
and physical exercise. bReference category. cThe sum of the strata does not add up to the total because of missing values.
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Although this is one of the largest case-control investigations of
colorectal cancer and aspirin, the number of regular aspirin users
(and hence the statistical power) is relatively low, reflecting the
pattern of aspirin use in Italy. Some of the diagnostic categories of
the controls may have been associated with increased NSAID use,
however separate comparison of cases with each of the major diag-
nostic categories of controls yielded similar results, thus providing
reassurance against potential selection bias. In particular, the
frequency of regular aspirin users was 3.7% among subjects with
traumatic conditions and 4.2% among those with non-traumatic
orthopaedic diseases.
Among the strengths of the study are the similar catchment
areas of cases and controls and the almost complete participation.
Furthermore, the choice of hospital controls has the advantage
with regard to the reliability and validity of drug use information,
as cases and controls should be similarly sensitized towards
various aspects of their past medical history (Paganini-Hill and
Ross, 1982; Kelly et al, 1990). Finally, allowance for potential
confounding factors, including measures of social class, an indi-
cator of physical exercise and selected dietary factors did not
materially modify any of the estimates.
Colorectal cancer is the commonest neoplasm in non-smokers
of both sexes in western countries (Levi et al, 1994), and a 30%
reduction of risk would be of considerable public health benefit.
Plausible biological mechanisms exist for a protective effect of
NSAIDS in colorectal carcinogenesis (Gann et al, 1993;
Greenberg and Baron, 1993). However, although we tried to avoid
or minimize the limitations of case-control studies, namely
possible selection, information bias and confounding, a 30%
reduction in an observational study of this kind is only modest, and
long-term clinical trials may still be required to properly address
the issue of aspirin and colorectal cancer.
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